Viking Therapeutics

5 Promising MASH Therapies That Could Follow Madrigal’s Rezdiffra
BioSpace
Mon, 04/15/24 - 11:24 am
MASH
NASH
Madrigal Pharmaceuticals
Rezdiffra
Ionis Pharmaceuticals
ION224
Altimmune
pemvidutid
89Bio
pegozafermin
Viking Therapeutics
VK2809
Aligos Therapeutics
ALG-055009
4 Investigational Weight Loss Drugs That Could Change the Market
BioSpace
Mon, 04/15/24 - 11:09 am
weight loss
Novo Nordisk
CagriSema
Eli Lilly
orforglipro
Viking Therapeutics
VK-2735
Inversago Pharma
INV-202
Viking touts promising phase I data for weight-loss pill candidate
BioSpace
Tue, 03/26/24 - 11:35 am
Viking Therapeutics
clinical trials
obesity
weight loss
VK2735
Could Viking Therapeutics Become the Next Eli Lilly?
Motley Fool
Fri, 03/22/24 - 09:27 am
Viking Therapeutics
Eli Lilly
weight loss
VK-2735
Zepbound
Mounjaro
Should Pfizer Acquire Viking Therapeutics to Take on Eli Lilly and Novo Nordisk in the Obesity Drug Market?
Motley Fool
Fri, 03/15/24 - 11:13 am
Pfizer
obesity
M&A
Viking Therapeutics
Viking Therapeutics' weight-loss drug trial success spurs share surge
Reuters
Tue, 02/27/24 - 11:34 am
Viking Therapeutics
weight loss
clinical trials
2 Rising Biotechs That Could Become the Next Novo Nordisk
Motley Fool
Mon, 01/29/24 - 11:04 am
Novo Nordisk
Madrigal Pharmaceuticals
Viking Therapeutics
NASH
NASH on the Cusp: An Emerging Market Opportunity
BioSpace
Mon, 10/23/23 - 09:53 am
NASH
Viking Therapeutics
Madrigal Pharmaceuticals
Terns Pharmaceuticals
Akero Therapeutics
Hepion Pharmaceuticals
Novo Nordisk
Galmed Pharmaceuticals
3 Biotechs Compete for the Same $108-Billion-Dollar Market
Motley Fool
Wed, 08/23/23 - 10:06 am
NASH
Madrigal Pharmaceuticals
Terns Pharmaceuticals
Viking Therapeutics
Prospective NASH market flips to over crowded as Big Pharma GLP-1s cast shadow over biotech breakthroughs
Fierce Biotech
Thu, 08/10/23 - 09:54 am
NASH
Terns Pharmaceuticals
Madrigal Pharmaceuticals
Viking Therapeutics
Major readouts on the horizon for small developers
EP Vantage
Fri, 03/31/23 - 10:19 am
Aldeyra Therapeutics
Autolus Therapeutics
Bavarian Nordic
BioXcel Therapeutics
Disc Medicine
Editas Medicine
Immunogen
Lantheus
Mersana Therapeutics
NGM Biopharmaceuticals
Omeros
Roche
Sutro BioPharma
uniQure
Valneva
Viking Therapeutics
Viking sets ships toward phase 2 after obesity med passes early test
Fierce Biotech
Tue, 03/28/23 - 10:48 pm
Viking Therapeutics
obesity
clinical trials
VK2735
Spotlight – What is next in Nash
EP Vantage
Fri, 03/3/23 - 10:02 am
NASH
clinical trials
89Bio
Arrowhead Pharmaceuticals
Can-Fite BioPharma
Ewopharma
Hepagene Therapeutics
JNJ
Ligand Pharmaceuticals
Madrigal Pharmaceuticals
Merck
NGM Biopharmaceuticals
NorthSea Therapeutics
Novartis
Sagimet Biosciences
Terns Pharmaceuticals
Viking Therapeutics
Catalysts ahead for the smaller players
EP Vantage
Wed, 12/21/22 - 11:19 am
89Bio
Altimmune
AnaptysBio
BioXcel Therapeutics
Calliditas Therapeutics
Eli Lilly
Esperion Therapeutics
Geron
Nektar Therapeutics
Oramed Pharmaceuticals
Pliant Therapeutics
Replimune
Selecta Biosciences
Swedish Orphan Biovitrum
Vera Therapeutics
Viking Therapeutics
1b, or not 1b: FDA hits Viking with clinical hold over mix-up in phase of rare disease trial
Fierce Biotech
Mon, 01/24/22 - 10:19 am
Viking Therapeutics
clinical trials
FDA
VK0214
metabolic disorders
Viking Therapeutics’ NASH Therapy Shows Major Reduction of Liver Fat and LDL Cholesterol
BioSpace
Thu, 11/19/20 - 10:27 am
Viking Therapeutics
NASH
VK2809
NASH drugmaker stocks rebound after dip on FDA guidance
Biopharma Dive
Mon, 06/10/19 - 06:08 pm
NASH
FDA
Madrigal Pharmaceuticals
Viking Therapeutics
Intercept Pharma
Genfit
Here's Why Madrigal Pharmaceuticals Fell 39.4% in November
Motley Fool
Sun, 12/9/18 - 03:55 pm
Madrigal Pharmaceuticals
NASH
MGL-3196
Viking Therapeutics
VK2809
3 Biotech Stocks That Soared This Week
Motley Fool
Sat, 09/22/18 - 05:31 pm
Viking Therapeutics
Acadia Pharmaceuticals
Corbus Pharmaceuticals
Promising study results thrust Viking Therapeutics into race for lucrative fatty liver disease treatment
Stat
Tue, 09/18/18 - 10:00 am
Viking Therapeutics
NASH
non-alcoholic fatty liver disease
VK2809
clinical trials

Pages